vs
Side-by-side financial comparison of Charles River Laboratories (CRL) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $994.2M, roughly 3.2× Charles River Laboratories). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs -27.8%, a 65.2% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs -0.8%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $58.6M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs -0.9%).
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
CRL vs VRTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $994.2M | $3.2B |
| Net Profit | $-276.6M | $1.2B |
| Gross Margin | — | 85.4% |
| Operating Margin | -28.5% | 37.8% |
| Net Margin | -27.8% | 37.3% |
| Revenue YoY | -0.8% | 9.5% |
| Net Profit YoY | -28.9% | 30.5% |
| EPS (diluted) | $-5.57 | $4.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $994.2M | $3.2B | ||
| Q3 25 | $1.0B | $3.1B | ||
| Q2 25 | $1.0B | $3.0B | ||
| Q1 25 | $984.2M | $2.8B | ||
| Q4 24 | $1.0B | $2.9B | ||
| Q3 24 | $1.0B | $2.8B | ||
| Q2 24 | $1.0B | $2.6B | ||
| Q1 24 | $1.0B | $2.7B |
| Q4 25 | $-276.6M | $1.2B | ||
| Q3 25 | $54.4M | $1.1B | ||
| Q2 25 | $52.3M | $1.0B | ||
| Q1 25 | $25.5M | $646.3M | ||
| Q4 24 | $-214.5M | $913.0M | ||
| Q3 24 | $69.7M | $1.0B | ||
| Q2 24 | $94.1M | $-3.6B | ||
| Q1 24 | $73.0M | $1.1B |
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | 34.6% | 85.8% | ||
| Q2 24 | 34.5% | 85.9% | ||
| Q1 24 | 34.1% | 87.3% |
| Q4 25 | -28.5% | 37.8% | ||
| Q3 25 | 13.3% | 38.6% | ||
| Q2 25 | 9.7% | 38.8% | ||
| Q1 25 | 7.6% | 22.7% | ||
| Q4 24 | -16.7% | 35.2% | ||
| Q3 24 | 11.6% | 40.3% | ||
| Q2 24 | 14.8% | -132.9% | ||
| Q1 24 | 12.5% | 42.4% |
| Q4 25 | -27.8% | 37.3% | ||
| Q3 25 | 5.4% | 35.2% | ||
| Q2 25 | 5.1% | 34.8% | ||
| Q1 25 | 2.6% | 23.3% | ||
| Q4 24 | -21.4% | 31.4% | ||
| Q3 24 | 6.9% | 37.7% | ||
| Q2 24 | 9.2% | -135.8% | ||
| Q1 24 | 7.2% | 40.9% |
| Q4 25 | $-5.57 | $4.64 | ||
| Q3 25 | $1.10 | $4.20 | ||
| Q2 25 | $1.06 | $3.99 | ||
| Q1 25 | $0.50 | $2.49 | ||
| Q4 24 | $-4.17 | $3.62 | ||
| Q3 24 | $1.33 | $4.01 | ||
| Q2 24 | $1.74 | $-13.92 | ||
| Q1 24 | $1.30 | $4.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.8M | $6.6B |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $3.2B | $18.7B |
| Total Assets | $7.1B | $25.6B |
| Debt / EquityLower = less leverage | 0.68× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.8M | $6.6B | ||
| Q3 25 | $207.1M | $6.3B | ||
| Q2 25 | $182.8M | $6.4B | ||
| Q1 25 | $229.4M | $6.2B | ||
| Q4 24 | $194.6M | $6.1B | ||
| Q3 24 | $210.2M | $6.5B | ||
| Q2 24 | $179.2M | $5.8B | ||
| Q1 24 | $327.0M | $10.2B |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $3.2B | $18.7B | ||
| Q3 25 | $3.4B | $17.3B | ||
| Q2 25 | $3.4B | $17.2B | ||
| Q1 25 | $3.2B | $16.5B | ||
| Q4 24 | $3.5B | $16.4B | ||
| Q3 24 | $3.8B | $15.6B | ||
| Q2 24 | $3.7B | $14.8B | ||
| Q1 24 | $3.6B | $18.5B |
| Q4 25 | $7.1B | $25.6B | ||
| Q3 25 | $7.5B | $24.9B | ||
| Q2 25 | $7.6B | $24.0B | ||
| Q1 25 | $7.6B | $22.9B | ||
| Q4 24 | $7.5B | $22.5B | ||
| Q3 24 | $8.0B | $22.2B | ||
| Q2 24 | $7.9B | $20.1B | ||
| Q1 24 | $8.2B | $23.9B |
| Q4 25 | 0.68× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.5M | $498.0M |
| Free Cash FlowOCF − Capex | $58.6M | $348.6M |
| FCF MarginFCF / Revenue | 5.9% | 10.9% |
| Capex IntensityCapex / Revenue | 8.9% | 4.7% |
| Cash ConversionOCF / Net Profit | — | 0.42× |
| TTM Free Cash FlowTrailing 4 quarters | $518.5M | $3.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.5M | $498.0M | ||
| Q3 25 | $213.8M | $1.2B | ||
| Q2 25 | $204.6M | $1.1B | ||
| Q1 25 | $171.7M | $818.9M | ||
| Q4 24 | $159.4M | $584.6M | ||
| Q3 24 | $251.8M | $1.4B | ||
| Q2 24 | $193.5M | $-3.8B | ||
| Q1 24 | $129.9M | $1.3B |
| Q4 25 | $58.6M | $348.6M | ||
| Q3 25 | $178.2M | $1.1B | ||
| Q2 25 | $169.3M | $927.4M | ||
| Q1 25 | $112.4M | $778.2M | ||
| Q4 24 | $83.7M | $492.0M | ||
| Q3 24 | $213.1M | $1.3B | ||
| Q2 24 | $154.0M | $-3.8B | ||
| Q1 24 | $50.7M | $1.2B |
| Q4 25 | 5.9% | 10.9% | ||
| Q3 25 | 17.7% | 37.0% | ||
| Q2 25 | 16.4% | 31.3% | ||
| Q1 25 | 11.4% | 28.1% | ||
| Q4 24 | 8.4% | 16.9% | ||
| Q3 24 | 21.1% | 47.0% | ||
| Q2 24 | 15.0% | -144.5% | ||
| Q1 24 | 5.0% | 46.0% |
| Q4 25 | 8.9% | 4.7% | ||
| Q3 25 | 3.5% | 3.3% | ||
| Q2 25 | 3.4% | 4.9% | ||
| Q1 25 | 6.0% | 1.5% | ||
| Q4 24 | 7.5% | 3.2% | ||
| Q3 24 | 3.8% | 2.4% | ||
| Q2 24 | 3.8% | 2.6% | ||
| Q1 24 | 7.8% | 2.5% |
| Q4 25 | — | 0.42× | ||
| Q3 25 | 3.93× | 1.15× | ||
| Q2 25 | 3.91× | 1.04× | ||
| Q1 25 | 6.74× | 1.27× | ||
| Q4 24 | — | 0.64× | ||
| Q3 24 | 3.61× | 1.31× | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
